Scenarios that move RARE

Ultragenyx Pharmaceutical Inc. - Common Stock

Scenarios that move RARE: 3 analyses, 2 positive, 1 negative.

1. 2026-10-15 · RARE's Fayuvi approval triggers second $203 million PRV sale — ▲ · impact +88 · confidence medium · horizon immediate
2. 2026-10-13 · Mirum's Livmarli meets Phase III goal in ultra-rare liver diseases — ▲ · impact +16 · confidence low · horizon quarters
3. 2026-09-30 · uniQure plunges after additional Huntington's disease study data — ▼ · impact -28 · confidence low · horizon quarters

All scenarios · Run a scenario · Pricing